Smart Pills Market Report 2025

This Smart Pills market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The smart pills market size has grown rapidly in recent years. It will grow from $5.39 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to medication adherence, chronic disease management, clinical trials and research, aging population.

The smart pills market size is expected to see rapid growth in the next few years. It will grow to $9.22 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to remote patient monitoring, regulatory and quality standards, clinical trials and research, digital health integration. Major trends in the forecast period include wireless health monitoring, diagnostic and imaging capsules, data analytics and artificial intelligence, smart pill sensors, miniaturization and biocompatibility.

The smart pills market is experiencing growth, driven by the increasing preference for non-invasive procedures. Non-invasive procedures refer to diagnostic and treatment methods that do not require incisions or tissue removal. Smart pills, which are wireless, ingestible capsules, are easily swallowed and have a wide range of applications in capsule endoscopy, drug delivery, and patient monitoring. For example, they play a crucial role in diagnostic imaging, particularly in capsule endoscopy, a procedure where a smart pill with a micro-camera is swallowed to capture images of the esophagus, stomach, and small intestine as it traverses the gastrointestinal (GI) tract. Smart pills have transformed the diagnosis of gastrointestinal disorders and have the potential to replace conventional techniques like endoscopy. Consequently, the preference for non-invasive procedures is a key driver of the smart pills market.

The growth of the smart pills market is expected to be further fueled by the increasing prevalence of gastrointestinal disorders. Gastrointestinal disorders affect the digestive system, including the stomach, intestines, and associated organs. Smart pills equipped with sensors and technology are utilized for monitoring and diagnosing gastrointestinal disorders, providing valuable insights into digestive system function. For example, as of September 2022, the National Library of Medicine reports that over 40% of people worldwide experience gastrointestinal problems such as diarrhea, constipation, and irritable bowel syndrome (IBS), with prevalence rates of 4.7%, 11.7%, and 4.1%, respectively. Therefore, the rising incidence of gastrointestinal disorders is a significant driver of the smart pills market.

Extensive research and development efforts are underway to harness miniature chips like Addressable Transmitters Operated as Magnetic Spins (ATOMS) for use in smart pills. ATOMS are silicon chip devices that use magnetic resonance imaging (MRI) principles to pinpoint the location of atoms within a patient's body using magnetic fields. They can be employed in ingestible smart pills for disease diagnosis and treatment from within the body, monitoring the gastrointestinal tract, blood, brain, and various health indicators like pH, temperature, pressure, and sugar concentrations. Additionally, they can be programmed to release medications. For instance, scientists at Caltech (California Institute of Technology) have developed a miniature medical chip for potential use as a smart pill.

Major companies in the smart pills market are concentrating on developing smart pills with customizable programs to gain a competitive advantage. Smart pills with customizable programs enable personalized drug delivery and health monitoring, enhancing patient care and treatment effectiveness. For example, in September 2022, HealthBeacon PLC, an Irish digital therapeutics company, introduced the HB Smart Pills Solution, aiding patients in managing up to nine oral medications at home. This technology aims to improve medication adherence, addressing the issue where one in two patients struggles to adhere to their medication schedules. The HB Smart Pills Solution seamlessly integrates with patient support programs, offering customizable options for patients as standalone solutions or as part of existing offerings.

Major companies operating in the smart pills market include Medtronic PLC, Olympus Corporation, CapsoVision Inc., Novartis AG, Proteus Digital Health Inc., Koninklijke Philips N.V., MicroCHIPS Inc., Bio-Images Drug Delivery (BDD) Ltd., Given Imaging Ltd., Vitality Inc., Boston Scientific Corporation, HQ Inc., Fujifilm Holdings Corporation, General Electric Company, Check-Cap Ltd., IntroMedic Co. Ltd., Jinshan Science & Technology Co. Ltd., PENTAX Medical, etectRx Inc., Pixie Scientific HQ Inc., ANX Robotica Corp., RF Co. Ltd., Shenzhen Jifu Medical Technology Co. Ltd., Otsuka America Pharmaceutical Inc., Medimetrics Personalized Drug Delivery B.V., Smart Pill Inc., Medisafe Inc., AdhereTech LLC, TabSafe Medical Services Inc.

Smart pills are designed for the purpose of administering medication and are equipped with electronic sensors that emit signals detectable by patches or smartphones upon ingestion. These innovative pills play a crucial role in ensuring patients' adherence to their prescribed drug regimens and enable the monitoring of medication compliance.

The primary applications of smart pills encompass capsule endoscopy, patient monitoring, and drug delivery. Patient monitoring involves the repeated or continuous tracking of various patient parameters. Smart pills are used to target specific areas within the gastrointestinal tract, including the esophagus, stomach, small intestine, and large intestine, for the treatment of conditions such as esophageal diseases, colon diseases, small bowel diseases, among others. These smart pills find utility in a variety of healthcare settings, including hospitals, diagnostic centers, and research institutes.

The smart pills market research report is one of a series of new reports that provides smart pills market statistics, including smart pills industry global market size, regional shares, competitors with a smart pills market share, detailed smart pills market segments, market trends and opportunities, and any further data you may need to thrive in the smart pills industry. This smart pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the smart pills market in 2024. Western Europe was the second-largest region in the smart pills market analysis. The regions covered in the smart pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The smart pills market consists of sales of instruments that are used in applications such as capsule endoscopy, drug delivery, and patient monitoring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.